Treatment of lower-risk myelodysplastic syndromes

Hamid Sayar, Bilal K. Siddiqui, Muhammad A. Jadoon

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In order to facilitate clinical decision on management of patients with myelodysplastic syndromes (MDS), arbitrary terminologies of lower-risk and higher-risk disease are typically utilized. In general, lower-risk disease includes the low and intermediate-1 risk groups under the International Prognostic Scoring System (IPSS), and higher-risk disease encompasses those in the intermediate-2 and high-risk categories. In the revised version of IPSS (IPSS-R), the very low and low-risk groups can be considered under lower-risk disease, high and very high risk groups under high-risk, and the intermediate group would lie between the two. Such stratification, however, is not secure from flaws and deficiencies. Moreover, particular patients may fall into a specific risk group, while they follow a different clinical course. This chapter will provide a review of management strategies for lower-risk MDS. A practical approach to the choice of initial and subsequent therapies will be offered with consideration of type and degree of cytopenia. In addition, specific topics of supportive care, approach to the treatment of MDS/MPN, and the issue of iron overload with frequent transfusions will be elaborated. Finally, relying on data from clinical trials, extensive discussion on therapeutic modalities including growth factors and immunosuppressive therapy will be offered.

Original languageEnglish
Title of host publicationMyelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy
PublisherNova Science Publishers, Inc.
Pages227-246
Number of pages20
ISBN (Print)9781624175749
StatePublished - Jan 2013

Fingerprint

Myelodysplastic Syndromes
Therapeutics
Iron Overload
Immunosuppressive Agents
Terminology
Intercellular Signaling Peptides and Proteins
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sayar, H., Siddiqui, B. K., & Jadoon, M. A. (2013). Treatment of lower-risk myelodysplastic syndromes. In Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy (pp. 227-246). Nova Science Publishers, Inc..

Treatment of lower-risk myelodysplastic syndromes. / Sayar, Hamid; Siddiqui, Bilal K.; Jadoon, Muhammad A.

Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy. Nova Science Publishers, Inc., 2013. p. 227-246.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sayar, H, Siddiqui, BK & Jadoon, MA 2013, Treatment of lower-risk myelodysplastic syndromes. in Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy. Nova Science Publishers, Inc., pp. 227-246.
Sayar H, Siddiqui BK, Jadoon MA. Treatment of lower-risk myelodysplastic syndromes. In Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy. Nova Science Publishers, Inc. 2013. p. 227-246
Sayar, Hamid ; Siddiqui, Bilal K. ; Jadoon, Muhammad A. / Treatment of lower-risk myelodysplastic syndromes. Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy. Nova Science Publishers, Inc., 2013. pp. 227-246
@inbook{25d10ffcc6ca4b318c2d3e003df17c8f,
title = "Treatment of lower-risk myelodysplastic syndromes",
abstract = "In order to facilitate clinical decision on management of patients with myelodysplastic syndromes (MDS), arbitrary terminologies of lower-risk and higher-risk disease are typically utilized. In general, lower-risk disease includes the low and intermediate-1 risk groups under the International Prognostic Scoring System (IPSS), and higher-risk disease encompasses those in the intermediate-2 and high-risk categories. In the revised version of IPSS (IPSS-R), the very low and low-risk groups can be considered under lower-risk disease, high and very high risk groups under high-risk, and the intermediate group would lie between the two. Such stratification, however, is not secure from flaws and deficiencies. Moreover, particular patients may fall into a specific risk group, while they follow a different clinical course. This chapter will provide a review of management strategies for lower-risk MDS. A practical approach to the choice of initial and subsequent therapies will be offered with consideration of type and degree of cytopenia. In addition, specific topics of supportive care, approach to the treatment of MDS/MPN, and the issue of iron overload with frequent transfusions will be elaborated. Finally, relying on data from clinical trials, extensive discussion on therapeutic modalities including growth factors and immunosuppressive therapy will be offered.",
author = "Hamid Sayar and Siddiqui, {Bilal K.} and Jadoon, {Muhammad A.}",
year = "2013",
month = "1",
language = "English",
isbn = "9781624175749",
pages = "227--246",
booktitle = "Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Treatment of lower-risk myelodysplastic syndromes

AU - Sayar, Hamid

AU - Siddiqui, Bilal K.

AU - Jadoon, Muhammad A.

PY - 2013/1

Y1 - 2013/1

N2 - In order to facilitate clinical decision on management of patients with myelodysplastic syndromes (MDS), arbitrary terminologies of lower-risk and higher-risk disease are typically utilized. In general, lower-risk disease includes the low and intermediate-1 risk groups under the International Prognostic Scoring System (IPSS), and higher-risk disease encompasses those in the intermediate-2 and high-risk categories. In the revised version of IPSS (IPSS-R), the very low and low-risk groups can be considered under lower-risk disease, high and very high risk groups under high-risk, and the intermediate group would lie between the two. Such stratification, however, is not secure from flaws and deficiencies. Moreover, particular patients may fall into a specific risk group, while they follow a different clinical course. This chapter will provide a review of management strategies for lower-risk MDS. A practical approach to the choice of initial and subsequent therapies will be offered with consideration of type and degree of cytopenia. In addition, specific topics of supportive care, approach to the treatment of MDS/MPN, and the issue of iron overload with frequent transfusions will be elaborated. Finally, relying on data from clinical trials, extensive discussion on therapeutic modalities including growth factors and immunosuppressive therapy will be offered.

AB - In order to facilitate clinical decision on management of patients with myelodysplastic syndromes (MDS), arbitrary terminologies of lower-risk and higher-risk disease are typically utilized. In general, lower-risk disease includes the low and intermediate-1 risk groups under the International Prognostic Scoring System (IPSS), and higher-risk disease encompasses those in the intermediate-2 and high-risk categories. In the revised version of IPSS (IPSS-R), the very low and low-risk groups can be considered under lower-risk disease, high and very high risk groups under high-risk, and the intermediate group would lie between the two. Such stratification, however, is not secure from flaws and deficiencies. Moreover, particular patients may fall into a specific risk group, while they follow a different clinical course. This chapter will provide a review of management strategies for lower-risk MDS. A practical approach to the choice of initial and subsequent therapies will be offered with consideration of type and degree of cytopenia. In addition, specific topics of supportive care, approach to the treatment of MDS/MPN, and the issue of iron overload with frequent transfusions will be elaborated. Finally, relying on data from clinical trials, extensive discussion on therapeutic modalities including growth factors and immunosuppressive therapy will be offered.

UR - http://www.scopus.com/inward/record.url?scp=84895251429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895251429&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84895251429

SN - 9781624175749

SP - 227

EP - 246

BT - Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy

PB - Nova Science Publishers, Inc.

ER -